June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Association between growth of geographic atrophy (GA) and the complement factor I (CFI) Locus
Author Affiliations & Notes
  • Zohar Yehoshua
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
  • Carlos Alexandre de Amorim Garcia Filho
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
  • Renata Portella Nunes
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
    Department of Ophthalmology and Visual Science, Paulista School of Medicine, Sao Paulo, Brazil
  • Giovanni Gregori
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
  • Fernando M Penha
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
  • Andrew A Moshfeghi
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
    University of Southern California, Los Angeles, CA
  • Kang Zhang
    Shiley Eye Center, University of California, San Diego, La Jolla, CA
  • Srinivas R Sadda
    Doheny Eye Center, Los Angeles, CA
  • William J Feuer
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
  • Philip J Rosenfeld
    Bascom Palmer Eye Institute, University of Miami, Miami, FL
  • Footnotes
    Commercial Relationships Zohar Yehoshua, Carl Zeiss (F); Carlos Alexandre de Amorim Garcia Filho, Carl Zeiss (F); Renata Portella Nunes, None; Giovanni Gregori, Carl Zeiss (F), Carl Zeiss (P); Fernando Penha, Carl Zeiss (F); Andrew Moshfeghi, Alimera (C), Alcon (C), Alexion (C), Allergan (C), Genetech (C), Regeneron (C); Kang Zhang, Acucela (C), Genentech (F); Srinivas Sadda, Allergan (C), Allergan (F), Carl Zeiss (C), Carl Zeiss (F), Carl Zeiss (R), Genetech (C), Genetech (F), Novartis (C), Optos (C), Optos (F), Optos (R), Roche (C); William Feuer, None; Philip Rosenfeld, Alexion Pharmaceuticals (F), Carl Zeiss (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2845. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zohar Yehoshua, Carlos Alexandre de Amorim Garcia Filho, Renata Portella Nunes, Giovanni Gregori, Fernando M Penha, Andrew A Moshfeghi, Kang Zhang, Srinivas R Sadda, William J Feuer, Philip J Rosenfeld; Association between growth of geographic atrophy (GA) and the complement factor I (CFI) Locus. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2845.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate whether the at-risk SNP in the CFI locus, which was found to be associated with rapid progression of geographic atrophy in the MAHALO trial, was also associated with an increased growth of GA in COMPLETE trial participants.

 
Methods
 

Blood samples collected from the 30 COMPLETE trial GA patients were genotyped using the following SNPs: complement factor I (CFI) (rs17440077), complement factor H (CFH)(rs1329428), and C3 (rs 2230199) C2/CFB (rs429608) (Yaspan, B. ARVO 2014, Abstract 2234, A common SNP at the CFI locus is associated with rapid progression og GA).GA growth was measured using autofluorescence imaging with a fundus camera-based flash system and confocal scanning laser ophthalmoscopy system, as well as spectral-domain (SD) optical coherence tomography (OCT). OCT fundus images were derived from a slab beneath the retinal pigment epithelium (sub-RPE slab). Growth of GA in the 24 study eyes of COMPLETE patients meeting MAHALO eligibility criteria was compared between those carrying and not carrying the CFI at risk allele using the 2 sample t-test.

 
Results
 

The prevalence of at-risk alleles among the 30 patients in the complete study was: CFI, 19 (63%); CFH, 28 (93%); C3, 11 (36%); C2/B, 30 (100%). Growth of GA in eyes of patients without the CFI at risk allele was slightly, but not significantly faster than growth in eyes of those carrying the CFI at risk allele (P≥0.55). Growth rate based on the sub-RPE slab at 52 week was 2.05±1.13mm2 (0.40±0.21 mm using the difference in the square root of the areas) for patients without any CFI at-risk alleles and 1.83±1.41mm2 (0.36±0.23 mm using the difference in the square root of the areas) for patients with at least one CFI at-risk allele (P≥0.7).

 
Conclusions
 

The COMPLETE study is small but similar in size to the MAHALO trial. In contrast to the MAHALO trial, COMPLETE patients, who were carriers of the at-risk allele for CFI, were not found to have faster progression of GA compared with those without the at-risk allele. Additional and larger studies are needed to confirm or refute the association of CFI with GA progression.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×